The global antisense
and RNAi therapeutics market is anticipated to reach USD 4.58 billion
by 2022, according to a new report by Grand View Research, Inc. Technological
development in the drug delivery technology based on liposome and nano
biotechnology is expected to provide the market with a high potential to grow
due to enhancement in the adoption of gene silencing therapeutic product
models.
The RNAi therapeutic industry has an extensive product
portfolio in the pipeline and expected commercialization of these products is
expected to fuel growth in demand over the next seven years.
A number of major market participants have strong
intellectual property portfolios for various RNAi related methods and usages,
based on which there are a considerable number of therapeutics in different
phases of discovery, and development clinical trials for mainly cancer and
cardiology associated disorders.
Furthermore, strategic collaborations intended by the
market participants for availing licensed developmental use for proprietary
RNAi technology platforms is another major source for generation of revenue in the
market from amongst these entities.
Browse full research report on Antisense and RNAi Therapeutics Market: https://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market
Further
key findings from the report suggest:
- RNA interference accounted for the largest share of market revenue
in 2014 owing to the ability of RNA-blocking oligo nucleotides in the
manipulation of gene function that makes them best suited for the
treatment of genetic disorders and other chronic diseases.
- Moreover, positive results obtained from the clinical trials for
the treatment of Duchenne muscular dystrophy prove that this technology is
close to achieving its clinical potential. RNAi can also be employed for
reduction of the levels of toxic gain-of-function proteins, block viral
replication, and trigger cytotoxicity within tumors.
- Applications of RNAi therapeutics in oncology accounted for a
sizeable 19% of the revenue generated in 2014. Higher incidence of cancer
extenuates the need for extensive R&D investment for cancer
therapeutics.
- Due to the growing need for unconventional methods to check cancer
associated mortality, market participants are involved in the development
&introduction of novel biomolecules that can be used with a higher
efficiency in targeting different cell surface receptors and tumor marker
genes in attempts to prevent post-translational tumor modifications.
- Developmental revenue flowing into R&D for RNAi delivery
through pulmonary routes of administration dominated the segment in 2014
owing to higher efficacy exhibited by the clinical trials based on the
respiration based routes of drug transfer for a number of lungs associated
disorders.
- A number of delivery technologies are under focused investigation
to evolve the current methods further and enhance efficiency to other
specific organ targets as well. The presence of several drugs in the
phases of clinical trials for administration via systemic and pulmonary
route is a supportive factor expected to drive growth in this
sector.
- North America dominated the industry in 2014, with revenue
estimated at over USD 400 million. Presence of a number of major market
entities headquartered in this region coupled with their collaborations
with academic institutions and smaller clinical stage biopharmaceutical
companies for research is expected to impact growth positively over the
forecast period.
- Key players operating in this market include Tekmira
Pharmaceuticals/Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense
Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics,
Santaris / Roche.
- These entities are involved in a significant number of
collaborations for RNAi R&D with clinical research organizations,
therapeutic product discovery and development laboratories, and academic
institutes in order to reduce the in-house expenses involved in the
discovery, development, and preclinical development.
- Moreover, focus on product versus platform technologies and virtual
drug development models that enable companies to reduce the research cost
coupled with target specificity and selectivity associated with the use of
RNAi therapeutics are factors expected to serve the market with a number
of lucrative avenues to grow through to 2022.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand
View Research has segmented Antisense and RNAi therapeutics market on the basis
of technology, application, route of administration and region:
Global RNAi
and Antisense Therapeutics Market, by Technology (Revenue, USD Million, 2012 -
2022)
- RNAi
- siRNA
- miRNA
- Antisense RNA
Global RNAi
and Antisense Therapeutics Market, by Application (Revenue, USD Million, 2012 -
2022)
- Oncology
- Cardiovascular
- Renal Diseases
- Neurodegenerative
Disorders
- Respiratory
Disorders
- Genetic
Disorders
- Infectious
Diseases
- Other
Global RNAi
and Antisense Therapeutics Market, by Route of Administration (Revenue, USD
Million, 2012 - 2022)
- Pulmonary
Delivery
- Intravenous
Injections
- Intradermal
Injections
- Intraperitoneal
Injections
- Topical
Delivery
- Other
Delivery Methods
Global RNAi
and Antisense Therapeutics Market, by Region (Revenue, USD Million, 2012 -
2022)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- MEA
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment